专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090299039A1 ANTI-A33 ANTIBODY 审中-公开
标题翻译：抗AN33抗体
公开(公告)号：US20090299039A1
公开(公告)日：2009-12-03
申请号：US12421431
申请日：2009-04-09
申请人： Shiro Kataoka , Takafumi Tomura , Noriko Otani
发明人： Shiro Kataoka , Takafumi Tomura , Noriko Otani
IPC分类号： C07K16/30 , A61P35/00 , C12N5/16 , C12P21/02
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2803 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/732 , C07K2317/734 , C07K2317/76
摘要： The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or therapeutic agent for various malignant tumors including solid tumors that are currently treated with difficulty, which contains the antibody or an antibody fragment thereof. Specifically, the antibody or a functional fragment thereof is capable of binding to A33 and is produced by a hybridoma M10 (accession No. FERM BP-10107), M96 (accession No. FERM BP-10108), M 165 (accession No. FERM BP-10106), N26 (accession No. FERM BP-10109), Q47 (accession No. FERM BP-10104), Q54 (accession No. FERM BP-10105), or R5 (accession No. FERM BP-10107). The preventive or therapeutic agent for tumors contains the antibody or a functional fragment thereof.
摘要翻译：本发明提供：可以结合A33的抗体或其抗体片段，其特异性地使用基于免疫系统的ADCC和CDC，并且不产生HAHA特异性攻击表达A33的肿瘤细胞; 以及包含抗体或其抗体片段的目前难以治疗的各种恶性肿瘤（包括实体瘤）的预防或治疗剂。具体地，抗体或其功能片段能够结合A33，并且由杂交瘤M10（登录号FERM BP-10107），M96（登录号FERM BP-10108），M 165（登录号FERM BP-10106），N26（登录号FERM BP-10109），Q47（登录号FERM BP-10104），Q54（登录号FERM BP-10105）或R5（登录号FERM BP-10107）。肿瘤的预防或治疗剂含有抗体或其功能片段。

2. 发明授权

US07432359B2 Anti-A33 antibody 失效
标题翻译：抗A33抗体
公开(公告)号：US07432359B2
公开(公告)日：2008-10-07
申请号：US12053461
申请日：2008-03-21
申请人： Shiro Kataoka , Takafumi Tomura , Noriko Otani
发明人： Shiro Kataoka , Takafumi Tomura , Noriko Otani
IPC分类号： C07K16/00 , C12P21/08 , A61K39/395 , C12P21/04 , C12P21/082 , C07H21/04
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/30 , C07K2317/21 , C07K2317/56 , C07K2317/732 , C07K2317/734 , C07K2317/76
摘要： The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or therapeutic agent for various malignant tumors including solid tumors that are currently treated with difficulty, which contains the antibody or an antibody fragment thereof. Specifically, the antibody or a functional fragment thereof is capable of binding to A33 and is produced by a hybridoma M10 (accession No. FERM BP-10107), M96 (accession No. FERM BP-10108), M165 (accession No. FERM BP-10106), N26 (accession No. FERM BP-10109), Q47 (accession No. FERM BP-10104), Q54 (accession No. FERM BP-10105), or R5 (accession No. FERM BP-10107). The preventive or therapeutic agent for tumors contains the antibody or a functional fragment thereof.
摘要翻译：本发明提供：可以结合A33的抗体或其抗体片段，其特异性地使用基于免疫系统的ADCC和CDC，并且不产生HAHA特异性攻击表达A33的肿瘤细胞; 以及包含抗体或其抗体片段的目前难以治疗的各种恶性肿瘤（包括实体瘤）的预防或治疗剂。具体地，抗体或其功能片段能够结合A33，并且由杂交瘤M10（登录号FERM BP-10107），M96（登录号FERM BP-10108），M165（登录号FERM BP -10106），N26（登录号FERM BP-10109），Q47（登录号FERM BP-10104），Q54（登录号FERM BP-10105）或R5（登录号FERM BP-10107）。肿瘤的预防或治疗剂含有抗体或其功能片段。

3. 发明授权

US5910427A Antigen non-specific glycosylation inhibiting factor derivatives 失效
标题翻译：抗原非特异性糖基化抑制因子衍生物
公开(公告)号：US5910427A
公开(公告)日：1999-06-08
申请号：US610728
申请日：1996-03-04
申请人： Toshifumi Mikayama , Takafumi Tomura , Hiroshi Watarai , Ryota Kuroki , Yoichi Kato , Kimishige Ishizaka , Tatsumi Nakano
发明人： Toshifumi Mikayama , Takafumi Tomura , Hiroshi Watarai , Ryota Kuroki , Yoichi Kato , Kimishige Ishizaka , Tatsumi Nakano
IPC分类号： C12N15/09 , A61K31/00 , A61K38/00 , A61P3/00 , A61P3/10 , A61P37/00 , A61P37/08 , C07K14/52 , C12N1/21 , C12N5/10 , C12N15/19 , C12P21/02 , C12P21/00 , A61K38/18 , C07K14/46
CPC分类号： C07K14/52 , A61K38/00
摘要： Antigen non-specific human glycosylation inhibiting factor derivatives having the inmunosuppressive activity in which a mutation was introduced for replacement, deletion and/or insertion of a part of the amino acid sequence of SEQ ID NO:21, and/or which has received a chemical modification of one or more amino acid residue(s) in the amino acid sequence of SEQ ID NO:21, wherein the mutation and the chemical modification attenuate the strength of an intermolecular association in the region, which participates in trimerization, of an antigen non-specific human glycosylation inhibiting factor having the amino acid sequence of SEQ ID NO:21; DNAs containing a base sequence encoding the amino acid sequence of the antigen non-specific human glycosylation inhibiting factor derivative; recombinant vectors containing the DNAs; prokaryotic or eukaryotic cells transformed with the DNAs; methods of producing the antigen non-specific human glycosylation inhibiting factor derivatives; pharmaceutical compositions comprising the antigen non-specific human glycosylation inhibiting factor derivative and a pharmaceutically acceptable carrier; and methods of suppressing a human immune response to an antigen are provided.
摘要翻译：抗原非特异性人糖基化抑制因子衍生物，其具有引入SEQ ID NO：21的氨基酸序列的一部分的替换，缺失和/或插入的突变的无效抑制活性，和/或已经接受了化学物质修饰SEQ ID NO：21的氨基酸序列中的一个或多个氨基酸残基，其中突变和化学修饰减弱参与三聚反应的区域中分子间缔合的强度，具有SEQ ID NO：21的氨基酸序列的特异性人糖基化抑制因子; 含有编码抗原非特异性人糖基化抑制因子衍生物的氨基酸序列的碱基序列的DNA; 含有DNA的重组载体; 用DNA转化的原核或真核细胞; 生产抗原非特异性人糖基化抑制因子衍生物的方法; 包含抗原非特异性人糖基化抑制因子衍生物和药学上可接受的载体的药物组合物; 并提供抑制对抗原的人免疫应答的方法。

4. 发明申请

US20070141054A1 Anti-a33 antibody 失效
标题翻译：抗-33抗体
公开(公告)号：US20070141054A1
公开(公告)日：2007-06-21
申请号：US11629779
申请日：2005-09-02
申请人： Shiro Kataoka , Takafumi Tomura , Noriko Otani
发明人： Shiro Kataoka , Takafumi Tomura , Noriko Otani
IPC分类号： A61K39/395 , C12N5/06
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2803 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/732 , C07K2317/734 , C07K2317/76
摘要： The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or therapeutic agent for various malignant tumors including solid tumors that are currently treated with difficulty, which contains the antibody or an antibody fragment thereof. Specifically, the antibody or a functional fragment thereof is capable of binding to A33 and is produced by a hybridoma M10 (accession No. FERM BP-10107), M96 (accession No. FERM BP-10108), M165 (accession No. FERM BP-10106), N26 (accession No. FERM BP-10109), Q47 (accession No. FERM BP-10104), Q54 (accession No. FERM BP-10105), or R5 (accession No. FERM BP-10107). The preventive or therapeutic agent for tumors contains the antibody or a functional fragment thereof.
摘要翻译：本发明提供：可以结合A33的抗体或其抗体片段，其特异性地使用基于免疫系统的ADCC和CDC，并且不产生HAHA特异性攻击表达A33的肿瘤细胞; 以及包含抗体或其抗体片段的目前难以治疗的各种恶性肿瘤（包括实体瘤）的预防或治疗剂。具体地，抗体或其功能片段能够结合A33，并且由杂交瘤M10（登录号FERM BP-10107），M96（登录号FERM BP-10108），M165（登录号FERM BP -10106），N26（登录号FERM BP-10109），Q47（登录号FERM BP-10104），Q54（登录号FERM BP-10105）或R5（登录号FERM BP-10107）。肿瘤的预防或治疗剂含有抗体或其功能片段。

5. 发明授权

US07579187B2 Anti-A33 antibody 失效
标题翻译：抗A33抗体
公开(公告)号：US07579187B2
公开(公告)日：2009-08-25
申请号：US11629779
申请日：2005-09-02
申请人： Shiro Kataoka , Takafumi Tomura , Noriko Otani
发明人： Shiro Kataoka , Takafumi Tomura , Noriko Otani
IPC分类号： C12N5/06 , C12N5/16 , C07K16/00 , A61K39/395 , C12P21/04 , G01N33/53 , C12P21/08
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2803 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/732 , C07K2317/734 , C07K2317/76
摘要： The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or therapeutic agent for various malignant tumors including solid tumors that are currently treated with difficulty, which contains the antibody or an antibody fragment thereof. Specifically, the antibody or a functional fragment thereof is capable of binding to A33 and is produced by a hybridoma M10 (accession No. FERM BP-10107), M96 (accession No. FERM BP-10108), M165 (accession No. FERM BP-10106), N26 (accession No. FERM BP-10109), Q47 (accession No. FERM BP-10104), Q54 (accession No. FERM BP-10105), or R5 (accession No. FERM BP-10107). The preventive or therapeutic agent for tumors contains the antibody or a functional fragment thereof.
摘要翻译：本发明提供：可以结合A33的抗体或其抗体片段，其特异性地使用基于免疫系统的ADCC和CDC，并且不产生HAHA特异性攻击表达A33的肿瘤细胞; 以及包含抗体或其抗体片段的目前难以治疗的各种恶性肿瘤（包括实体瘤）的预防或治疗剂。具体地，抗体或其功能片段能够结合A33，并且由杂交瘤M10（登录号FERM BP-10107），M96（登录号FERM BP-10108），M165（登录号FERM BP -10106），N26（登录号FERM BP-10109），Q47（登录号FERM BP-10104），Q54（登录号FERM BP-10105）或R5（登录号FERM BP-10107）。肿瘤的预防或治疗剂含有抗体或其功能片段。

6. 发明申请

US20080200654A1 ANTI-A33 ANTIBODY 失效
标题翻译：抗AN33抗体
公开(公告)号：US20080200654A1
公开(公告)日：2008-08-21
申请号：US12053461
申请日：2008-03-21
申请人： Shiro KATAOKA , Takafumi Tomura , Noriko Otani
发明人： Shiro KATAOKA , Takafumi Tomura , Noriko Otani
IPC分类号： C07K16/00
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/30 , C07K2317/21 , C07K2317/56 , C07K2317/732 , C07K2317/734 , C07K2317/76
摘要： The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or therapeutic agent for various malignant tumors including solid tumors that are currently treated with difficulty, which contains the antibody or an antibody fragment thereof. Specifically, the antibody or a functional fragment thereof is capable of binding to A33 and is produced by a hybridoma M10 (accession No. FERM BP-10107), M96 (accession No. FERM BP-10108), M165 (accession No. FERM BP-10106), N26 (accession No. FERM BP-10109), Q47 (accession No. FERM BP-10104), Q54 (accession No. FERM BP-10105), or R5 (accession No. FERM BP-10107). The preventive or therapeutic agent for tumors contains the antibody or a functional fragment thereof.
摘要翻译：本发明提供：可以结合A33的抗体或其抗体片段，其特异性地使用基于免疫系统的ADCC和CDC，并且不产生HAHA特异性攻击表达A33的肿瘤细胞; 以及包含抗体或其抗体片段的目前难以治疗的各种恶性肿瘤（包括实体瘤）的预防或治疗剂。具体地，抗体或其功能片段能够结合A33，并且由杂交瘤M10（登录号FERM BP-10107），M96（登录号FERM BP-10108），M165（登录号FERM BP -10106），N26（登录号FERM BP-10109），Q47（登录号FERM BP-10104），Q54（登录号FERM BP-10105）或R5（登录号FERM BP-10107）。肿瘤的预防或治疗剂含有抗体或其功能片段。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式